Display options
Cite
Alore EA, Suliburk JW, Ramsey DJ, et al. Diagnosis and Management of Primary Hyperparathyroidism Across the Veterans Affairs Health Care System. JAMA Intern Med. 2019;179(9):1220-1227doi: 10.1001/jamainternmed.2019.1747.
Alore, E. A., Suliburk, J. W., Ramsey, D. J., Massarweh, N. N., Balentine, C. J., Singh, H., Awad, S. S., & Makris, K. I. (2019). Diagnosis and Management of Primary Hyperparathyroidism Across the Veterans Affairs Health Care System. JAMA internal medicine, 179(9), 1220-1227. https://doi.org/10.1001/jamainternmed.2019.1747
Alore, Elizabeth A, et al. "Diagnosis and Management of Primary Hyperparathyroidism Across the Veterans Affairs Health Care System." JAMA internal medicine vol. 179,9 (2019): 1220-1227. doi: https://doi.org/10.1001/jamainternmed.2019.1747
Alore EA, Suliburk JW, Ramsey DJ, Massarweh NN, Balentine CJ, Singh H, Awad SS, Makris KI. Diagnosis and Management of Primary Hyperparathyroidism Across the Veterans Affairs Health Care System. JAMA Intern Med. 2019 Sep 01;179(9):1220-1227. doi: 10.1001/jamainternmed.2019.1747. PMID: 31305864; PMCID: PMC6632180.
Copy Download .nbib Format: NLM
Share it on

JAMA Intern Med. 2019 Sep 01;179(9):1220-1227. doi: 10.1001/jamainternmed.2019.1747.

Diagnosis and Management of Primary Hyperparathyroidism Across the Veterans Affairs Health Care System.

JAMA internal medicine

Elizabeth A Alore, James W Suliburk, David J Ramsey, Nader N Massarweh, Courtney J Balentine, Hardeep Singh, Samir S Awad, Konstantinos I Makris

Affiliations

  1. Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
  2. Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Health Services Research and Development Center of Innovation, Houston, Texas.
  3. Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
  4. Department of Surgery, University of Texas Southwestern, Dallas.
  5. Veterans Affairs North Texas Health Care System, Dallas.
  6. Department of Medicine, Baylor College of Medicine, Houston, Texas.

PMID: 31305864 PMCID: PMC6632180 DOI: 10.1001/jamainternmed.2019.1747

Abstract

IMPORTANCE: Untreated primary hyperparathyroidism impairs quality of life and incurs substantial costs. Parathyroidectomy is a low-risk, high-success, definitive intervention.

OBJECTIVES: To determine the appropriateness of diagnostic evaluation for primary hyperparathyroidism in patients with hypercalcemia and the use of parathyroidectomy for the treatment of primary hyperparathyroidism across the Veterans Affairs (VA) health care system.

DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of veterans with hypercalcemia and primary hyperparathyroidism was conducted from January 1, 2000, through September 30, 2015, using the VA Corporate Data Warehouse, a national electronic health record-based repository. The study included 371 370 veterans with chronic hypercalcemia and 47 158 veterans with biochemical evidence of primary hyperparathyroidism diagnosed by hypercalcemia, elevated serum parathyroid hormone levels, and near-normal serum creatinine levels. Statistical analysis was performed from April 21, 2017, to April 10, 2019.

MAIN OUTCOMES AND MEASURES: The proportion of veterans with hypercalcemia who have parathyroid hormone levels evaluated, the proportion of veterans with hyperparathyroidism who are treated surgically, and the factors associated with parathyroidectomy using generalized linear latent and mixed model regression.

RESULTS: Of 371 370 patients with chronic hypercalcemia, 86 887 (23.4%) received further testing with parathyroid hormone level. Of 47 158 patients meeting diagnostic criteria for primary hyperparathyroidism (42 737 men [90.6%] and 4421 women [9.4%]; mean [SD] age, 67.3 [11.8] years), 6048 (12.8%) underwent parathyroidectomy. Of 5793 patients with primary hyperparathyroidism presenting with a serum calcium level more than 1 mg/dL above the upper limit of normal, 1501 (25.9%) underwent parathyroidectomy. There was a decreasing trend in the use of parathyroidectomy over time. Factors positively associated with parathyroidectomy were nephrolithiasis (odds ratio [OR], 2.23; 95% CI, 1.90-2.61) and non-Hispanic white race/ethnicity (OR, 1.31; 95% CI, 1.17-1.46), while age (OR, 0.95; 95% CI, 0.95-0.96), Elixhauser Comorbidity Index score (OR, 0.76; 95% CI, 0.72-0.80), decreased estimated glomerular filtration rate (OR, 0.52; 95% CI, 0.45-0.60), and diagnosis of osteoporosis (OR, 0.65; 95% CI, 0.52-0.80) were inversely related to surgery.

CONCLUSIONS AND RELEVANCE: From this study's findings, parathyroid hormone level is infrequently tested in patients with hypercalcemia, suggesting underdiagnosis of primary hyperparathyroidism. Patients meeting diagnostic criteria for primary hyperparathyroidism are undertreated with recommended parathyroidectomy. Similar gaps have previously been observed in non-VA care of primary hyperparathyroidism, suggesting the need for a systematic evaluation of barriers to diagnosis and treatment that informs intervention design.

Publication Types